No Data
No Data
Scotiabank Initiates Coverage On Aclaris Therapeutics With Sector Outperform Rating, Announces Price Target of $15
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Cuts Target Price to $2
Unlock the Full List